United Therapeutics Q1 2024 GAAP EPS $6.17 Beats $5.56 Estimate, Sales $677.700M Beat $623.966M Estimate
United Therapeutics Q1 2024 GAAP EPS $6.17 Beats $5.56 Estimate, Sales $677.700M Beat $623.966M Estimate
United Therapeutics 2024年第一季度GAAP每股收益为6.17美元，超过预期的5.56美元，销售额为6.777亿美元，超过6.23966亿美元的预期
United Therapeutics (NASDAQ:UTHR) reported quarterly earnings of $6.17 per share which beat the analyst consensus estimate of $5.56 by 10.97 percent. This is a 26.95 percent increase over earnings of $4.86 per share from the same period last year. The company reported quarterly sales of $677.700 million which beat the analyst consensus estimate of $623.966 million by 8.61 percent. This is a 33.70 percent increase over sales of $506.900 million the same period last year.
联合疗法（纳斯达克股票代码：UTHR）公布的季度收益为每股6.17美元，比分析师普遍预期的5.56美元高出10.97％。这比去年同期的每股收益4.86美元增长了26.95％。该公司公布的季度销售额为6.777亿美元，比分析师普遍预期的6.23966亿美元高出8.61％。这比去年同期的5.069亿美元销售额增长了33.70％。